Welcome to our dedicated page for Trevi Therapeutics news (Ticker: TRVI), a resource for investors and traders seeking the latest updates and insights on Trevi Therapeutics stock.
Trevi Therapeutics, Inc. (Nasdaq: TRVI) is a clinical-stage biopharmaceutical company developing Haduvio™ (oral nalbuphine extended-release) as an investigational therapy for chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). The Trevi Therapeutics news feed on this page brings together company announcements, clinical data updates, and financial disclosures that relate directly to TRVI stock and its development programs.
News items commonly include results from key clinical trials such as the Phase 2b CORAL trial in IPF chronic cough and the Phase 2a RIVER trial in RCC, along with information on additional studies like respiratory safety and drug–drug interaction trials. Trevi’s releases also describe regulatory milestones, including End-of-Phase 2 interactions with the U.S. Food and Drug Administration for chronic cough in IPF, and outline planned Phase 3 and Phase 2b programs.
Investors and followers of TRVI can also find corporate and financial updates in the news stream, including quarterly financial results, capital-raising transactions, and participation in healthcare and investor conferences. Management changes and other material events are typically reported through press releases that are also furnished to the U.S. Securities and Exchange Commission on Form 8-K.
By reviewing the Trevi Therapeutics news page, readers can monitor how the company reports progress in its chronic cough indications, how clinical data are presented at scientific meetings, and how management describes its strategy for advancing Haduvio. This centralized news view helps provide context for developments that may influence perceptions of Trevi’s clinical pipeline and regulatory trajectory.
Trevi Therapeutics (NASDAQ: TRVI), a clinical-stage biopharmaceutical company developing Haduvio™ (oral nalbuphine ER) for chronic cough treatments, announced its participation in three major conferences in June 2025. The company will present at the American Cough Conference (June 6-7) discussing RIVER trial demographics for refractory chronic cough. At the CPDD 87th Annual Scientific Meeting (June 14-18), they will present research on nalbuphine's human abuse potential. Finally, at the BIO International Convention (June 16-19), the company will deliver a corporate presentation. Key executives, including CEO Jennifer Good and other senior management, will represent Trevi at these events.
- Statistically significant responder analyses across all doses at 30%, 50%, and 75% thresholds
- Significant improvement in Leicester Cough Questionnaire at Day 21
- Adverse events were more common during initial exposure (27mg BID) but decreased over time
- Most discontinuations occurred in first two weeks due to CNS and GI-related adverse events
Trevi Therapeutics (NASDAQ: TRVI) has scheduled its Q1 2025 financial results and corporate update conference call for May 8, 2025, at 4:30 p.m. ET. The company, which is developing Haduvio™ (oral nalbuphine ER) for chronic cough treatment in patients with idiopathic pulmonary fibrosis (IPF) or refractory chronic cough (RCC), will host the event via conference call and live audio webcast. Investors can join by dialing (877) 870 4263 (domestic) or (412) 317 0790 (international). The webcast will be available through the 'Investors & News' section on Trevi's website and archived for 30 days afterward.
Trevi Therapeutics (Nasdaq: TRVI), developing Haduvio™ (oral nalbuphine ER) for chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), has announced its participation in three major investor conferences this April 2025.
The company will present at the following events:
- 24th Annual Needham Virtual Healthcare Conference (April 7-10) with a corporate presentation on April 7 at 11:00-11:40 a.m. ET
- Jones Healthcare and Technology Innovation Conference (April 8-9) in Las Vegas, with a presentation on April 9 at 11:00-11:20 a.m. PT
- Piper Sandler Spring Biopharma Symposium (April 16-17) in Boston
Trevi Therapeutics (NASDAQ: TRVI) reported significant progress in its clinical trials for Haduvio, a therapy for chronic cough conditions. The company announced positive topline data from Phase 2a RIVER trial showing a 57% placebo-adjusted reduction in 24-hour cough frequency for refractory chronic cough patients.
Key developments include completed enrollment in the Phase 2b CORAL trial for IPF chronic cough patients, with topline data expected in Q2 2025, and positive sample size re-estimation outcome requiring no changes to the study. The company also reported positive results from its Human Abuse Potential study.
Financial highlights for Q4 2024:
- Cash position: $107.6 million, with runway into H2 2026
- R&D expenses: $9.3 million (up from $6.5M in Q4 2023)
- Net loss: $11.4 million (compared to $7.8M in Q4 2023)
Trevi Therapeutics (NASDAQ: TRVI) has scheduled its fourth quarter and year-end 2024 financial results announcement and corporate update for March 18, 2025, at 4:30 p.m. ET. The company, which is developing Haduvio™ (oral nalbuphine ER) for chronic cough treatment in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), will host a conference call and live audio webcast.
Participants can join via phone at (877) 870 4263 (domestic) or (412) 317 0790 (international). The webcast will be available through the 'Investors & News' section on Trevi's website, with a 30-day replay option available after the event.
Trevi Therapeutics (NASDAQ: TRVI) announced positive topline results from its Phase 2a RIVER trial evaluating Haduvio for refractory chronic cough (RCC). The trial met its primary endpoint with a 57% placebo-adjusted reduction in 24-hour cough frequency (p<0.0001).
Key findings include:
- 67% reduction in cough frequency from baseline
- 66% reduction in severe cough subgroup
- 68% reduction in moderate cough subgroup
- 84% of Haduvio patients achieved at least 30% reduction in cough frequency vs 29% for placebo
The trial involved 66 patients in a randomized, double-blind, placebo-controlled crossover study. Significant improvements were observed as early as Day 7 at the lowest dose (27mg BID). Common side effects included constipation, nausea, somnolence, headache, dizziness, and fatigue, with no serious adverse events reported.
Trevi Therapeutics (NASDAQ: TRVI) has scheduled a conference call and webcast for March 10th, 2025, at 8:30 a.m. ET to present topline results from their Phase 2a RIVER trial of Haduvio™. The trial evaluates oral nalbuphine ER for treating chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC).
The presentation will include audio and slides, accessible via webcast. Participants can join by dialing (877) 870 4263 (domestic) or (412) 317 0790 (international). A 30-day replay will be available on the company's website after the event.